ValuEngine upgraded shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) from a sell rating to a hold rating in a research report report published on Tuesday, June 27th.
AST has been the subject of a number of other research reports. FBR & Co restated an outperform rating and set a $6.00 price objective (down previously from $10.00) on shares of Asterias Biotherapeutics in a research report on Tuesday, March 7th. Zacks Investment Research upgraded Asterias Biotherapeutics from a hold rating to a buy rating and set a $3.50 price target for the company in a research report on Tuesday, March 21st.
Shares of Asterias Biotherapeutics (AST) opened at 3.55 on Tuesday. The stock’s market cap is $174.88 million. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $3.68. Asterias Biotherapeutics has a 52 week low of $2.54 and a 52 week high of $5.80.
TRADEMARK VIOLATION NOTICE: This article was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://transcriptdaily.com/2017/07/10/asterias-biotherapeutics-inc-ast-lifted-to-hold-at-valuengine-updated.html.
An institutional investor recently bought a new position in Asterias Biotherapeutics stock. Oxford Asset Management bought a new stake in shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 48,790 shares of the biotechnology company’s stock, valued at approximately $224,000. Oxford Asset Management owned 0.11% of Asterias Biotherapeutics as of its most recent filing with the SEC.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.